T1	ANAT 90 113	NERVIO TIBIAL POSTERIOR
#1	AnnotatorNotes T1	C0936237; Posterior Tibial Nerve; Body Part, Organ, or Organ Component
T2	CHEM 132 144	SOLIFENACINA
#2	AnnotatorNotes T2	C1099677; solifenacin; Organic Chemical · Pharmacologic Substance
T3	PROC 157 168	TRATAMIENTO
#3	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	PROC 46 113	NEUROMODULACION TRANSCUTANEA PERIFÉRICA DEL NERVIO TIBIAL POSTERIOR
#4	AnnotatorNotes T4	C2957505; neurostimulation of posterior tibial nerve by percutaneous needle electrode; Therapeutic or Preventive Procedure
T5	DISO 173 203	SÍNDROME DE VEJIGA HIPERACTIVA
#5	AnnotatorNotes T5	C4020898; Overactive bladder syndrome; Disease or Syndrome
T6	PROC 205 248	ENSAYO ALEATORIO FASE IV DE NO INFERIORIDAD
T7	DISO 273 295	Incontinencia urinaria
#6	AnnotatorNotes T7	C0042024; Urinary Incontinence; Pathologic Function
T8	PROC 115 121	T-PTNS
#7	AnnotatorNotes T8	C2957505; neurostimulation of posterior tibial nerve by percutaneous needle electrode; Therapeutic or Preventive Procedure
T9	DISO 322 352	Síndrome de vejiga hiperactiva
#8	AnnotatorNotes T9	C4020898; Overactive bladder syndrome; Disease or Syndrome
T10	PROC 397 411	diagnosticadas
#9	AnnotatorNotes T10	C0011900; Diagnosis; Diagnostic Procedure
T11	CHEM 477 493	Beta 3 agonistas
T12	CHEM 619 644	fármacos anticolinérgicos
#11	AnnotatorNotes T12	C0242896; Anticholinergic Agents; Pharmacologic Substance
T13	DISO 669 688	efectos secundarios
#12	AnnotatorNotes T13	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T14	DISO 698 716	vejiga hiperactiva
#13	AnnotatorNotes T14	C0341736; Neurogenic detrusor overactivity; Pathologic Function | C0878773; Overactive Bladder; Disease or Syndrome
T15	DISO 740 759	esclerosis múltiple
#14	AnnotatorNotes T15	C0026769; Multiple Sclerosis; Disease or Syndrome
T16	DISO 761 770	Parkinson
#15	AnnotatorNotes T16	C0030567; Parkinson Disease; Disease or Syndrome | C0242422; Parkinsonian Disorders; Disease or Syndrome
T17	DISO 772 790	lesiones medulares
#16	AnnotatorNotes T17	C0037929; Spinal Cord Injuries; Injury or Poisoning
T18	ANAT 781 790	medulares
#17	AnnotatorNotes T18	C0037925; Spinal Cord; Body Part, Organ, or Organ Component | C1278836; Entire spinal cord; Body Part, Organ, or Organ Component
T19	DISO 803 812	cistocele
#18	AnnotatorNotes T19	C0010695; Cystocele; Disease or Syndrome
T20	DISO 825 853	prolapso de órganos pélvicos
#19	AnnotatorNotes T20	C0877015; Pelvic Organ Prolapse; Disease or Syndrome
T21	ANAT 837 853	órganos pélvicos
T22	PROC 945 959	intervenciones
#20	AnnotatorNotes T22	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T23	CHEM 1037 1053	anticolinérgicos
#21	AnnotatorNotes T23	C0242896; Anticholinergic Agents; Pharmacologic Substance
T24	DISO 1059 1076	hipersensibilidad
#22	AnnotatorNotes T24	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T25	DISO 1078 1087	megacolon
#23	AnnotatorNotes T25	C0025160; Megacolon; Pathologic Function
T26	DISO 1089 1105	miastenia gravis
#24	AnnotatorNotes T26	C0026896; Myasthenia Gravis; Disease or Syndrome
T27	DISO 1107 1134	glaucoma de ángulo estrecho
#25	AnnotatorNotes T27	C0017605; Angle Closure Glaucoma; Disease or Syndrome
T28	DISO 1141 1162	alteraciones cutáneas
T29	ANAT 1166 1189	extremidades inferiores
#26	AnnotatorNotes T29	C0023216; Lower Extremity; Body Part, Organ, or Organ Component | C1269079; Entire lower limb; Body Part, Organ, or Organ Component
T30	PROC 1310 1324	ensayo clínico
#27	AnnotatorNotes T30	C0008976; Clinical Trials; Research Activity
T31	ANAT 185 191	VEJIGA
#28	AnnotatorNotes T31	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T32	ANAT 287 295	urinaria
#29	AnnotatorNotes T32	C0042036; Urine; Body Substance
T33	ANAT 334 340	vejiga
#30	AnnotatorNotes T33	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T34	ANAT 698 704	vejiga
#31	AnnotatorNotes T34	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T35	ANAT 1154 1162	cutáneas
#32	AnnotatorNotes T35	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T36	Date 13 17	2017
T37	Route 62 74	TRANSCUTANEA
T38	Dose 145 149	10mg
T40	LIVB 379 386	Mujeres
#33	AnnotatorNotes T40	C0043210; Woman; Population Group
T41	Age 387 395	>18 años
T42	Duration 428 444	al menos 6 meses
T43	LIVB 524 533	Pacientes
#34	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T47	LIVB 907 916	Pacientes
#35	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T50	DEVI 1001 1011	marcapasos
#36	AnnotatorNotes T50	C0030163; Artificial cardiac pacemaker; Medical Device
T51	Neg_cue 1021 1023	no
T53	Neg_cue 1194 1201	impidan
T54	DEVI 1219 1229	electrodos
#37	AnnotatorNotes T54	C0013812; electrode; Manufactured Object | C1283126; Neurostimulator electrode; Manufactured Object
T55	LIVB 1245 1264	mujeres embarazadas
#38	AnnotatorNotes T55	C0033011; Pregnant Women; Population Group
T39	DEVI 1012 1015	DAI
#39	AnnotatorNotes T39	C3874742; Cardiac resynchronization therapy implantable defibrillator; Medical Device
T44	PHYS 1253 1264	embarazadas
#40	AnnotatorNotes T44	C0032961; Pregnancy; Organism Function
A2	Assertion T23 Negated
A3	Assertion T54 Negated
A1	Status T11 History_of
A4	Status T12 History_of
A5	Status T13 History_of
A6	Status T24 History_of
#41	AnnotatorNotes T6	C0282462; Phase 4 Clinical Trials; Research Activity + C4505128; Non-Inferiority Trial; Research Activity
#10	AnnotatorNotes T21	C0230273; Pelvic viscus; Body Part, Organ, or Organ Component
#42	AnnotatorNotes T28	C0946387; Skin Integrity Alteration; Finding
T45	CONC 236 248	INFERIORIDAD
A7	Assertion T45 Negated
T46	Neg_cue 233 235	NO
T48	Neg_cue 649 657	falta de
T49	CONC 658 666	eficacia
#43	AnnotatorNotes T49	C1280519; Effectiveness; Qualitative Concept
A8	Assertion T49 Negated
R1	Has_Route_or_Mode Arg1:T4 Arg2:T37	
R2	Location_of Arg1:T1 Arg2:T4	
R3	Negation Arg1:T46 Arg2:T45	
R4	Location_of Arg1:T1 Arg2:T8	
R5	Has_Route_or_Mode Arg1:T8 Arg2:T37	
R6	Has_Dose_or_Strength Arg1:T2 Arg2:T38	
R7	Location_of Arg1:T31 Arg2:T5	
R8	Location_of Arg1:T32 Arg2:T7	
R9	Location_of Arg1:T33 Arg2:T9	
R10	Has_Age Arg1:T40 Arg2:T41	
R11	Experiences Arg1:T40 Arg2:T11	
T52	DISO 415 419	SVHI
#44	AnnotatorNotes T52	C4020898; Overactive bladder syndrome; Disease or Syndrome
R12	Has_Duration_or_Interval Arg1:T52 Arg2:T42	
R13	Experiences Arg1:T40 Arg2:T52	
R14	Experiences Arg1:T43 Arg2:T12	
R15	Negation Arg1:T48 Arg2:T49	
R16	Experiences Arg1:T43 Arg2:T13	
R17	Location_of Arg1:T34 Arg2:T14	
R18	Experiences Arg1:T43 Arg2:T14	
R19	Experiences Arg1:T43 Arg2:T15	
R20	Experiences Arg1:T43 Arg2:T16	
R21	Experiences Arg1:T43 Arg2:T17	
R22	Location_of Arg1:T18 Arg2:T17	
R23	Overlap Arg1:T14 Arg2:T15	
R24	Overlap Arg1:T14 Arg2:T16	
R25	Overlap Arg1:T14 Arg2:T17	
R26	Causes Arg1:T12 Arg2:T13	
R27	Experiences Arg1:T43 Arg2:T19	
R28	Experiences Arg1:T43 Arg2:T20	
R29	Location_of Arg1:T21 Arg2:T20	
T56	Quantifier_or_Qualifier 854 863	grado > 2
R30	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T56	
T57	CONC 873 895	clasificación de POP-Q
T58	Spec_cue 921 927	puedan
T59	Observation 928 936	empeorar
A9	Assertion T59 Speculated
#45	AnnotatorNotes T59	C1457868; Worse; Finding (?)
R31	Speculation Arg1:T58 Arg2:T59	
R32	Experiences Arg1:T47 Arg2:T59	
R33	Before Arg1:T22 Arg2:T59	
R34	Experiences Arg1:T47 Arg2:T22	
R35	Experiences Arg1:T47 Arg2:T50	
R36	Experiences Arg1:T47 Arg2:T39	
R37	Negation Arg1:T51 Arg2:T23	
R38	Experiences Arg1:T47 Arg2:T23	
R39	Causes Arg1:T23 Arg2:T24	
R40	Experiences Arg1:T47 Arg2:T24	
R41	Experiences Arg1:T47 Arg2:T25	
R42	Experiences Arg1:T47 Arg2:T26	
R43	Experiences Arg1:T47 Arg2:T27	
R44	Location_of Arg1:T35 Arg2:T28	
R45	Experiences Arg1:T47 Arg2:T28	
R46	Location_of Arg1:T29 Arg2:T28	
R47	Negation Arg1:T53 Arg2:T54	
R48	Experiences Arg1:T47 Arg2:T54	
R49	Overlap Arg1:T28 Arg2:T54	
R50	Experiences Arg1:T55 Arg2:T44	
R51	Overlap Arg1:T44 Arg2:T30	
R52	Before Arg1:T50 Arg2:T59	
R53	Before Arg1:T39 Arg2:T59	
R54	Before Arg1:T23 Arg2:T59	
#46	AnnotatorNotes T11	C2936485; Adrenergic beta-3 Receptor Agonists; Pharmacologic Substance (?)
#47	AnnotatorNotes T37	C5570969; Transcutaneous; Spatial Concept
A10	Experiencer T40 Patient
A11	Experiencer T43 Patient
A12	Experiencer T47 Patient
A13	Experiencer T55 Patient
A14	Status T22 Future
